Log in

Benitec Biopharma Stock Forecast, Price & News

+0.11 (+3.89 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $2.94
50-Day Range
MA: $2.86
52-Week Range
Now: $2.94
Volume422,810 shs
Average Volume498,485 shs
Market Capitalization$3.26 million
P/E RatioN/A
Dividend YieldN/A
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BNTC



Sales & Book Value

Annual Sales$100,000.00
Cash Flow$3.72 per share
Book Value$19.75 per share



Market Cap$3.26 million
Next Earnings DateN/A
OptionableNot Optionable
+0.11 (+3.89 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BNTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Benitec Biopharma (NASDAQ:BNTC) Frequently Asked Questions

How has Benitec Biopharma's stock price been impacted by COVID-19 (Coronavirus)?

Benitec Biopharma's stock was trading at $3.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BNTC stock has decreased by 23.2% and is now trading at $2.94.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Benitec Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Benitec Biopharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Benitec Biopharma?

Wall Street analysts have given Benitec Biopharma a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Benitec Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for BNTC?

1 brokerages have issued 12 month price targets for Benitec Biopharma's stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate Benitec Biopharma's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price.
View analysts' price targets for Benitec Biopharma

Are investors shorting Benitec Biopharma?

Benitec Biopharma saw a drop in short interest in October. As of October 30th, there was short interest totaling 5,800 shares, a drop of 68.0% from the October 15th total of 18,100 shares. Based on an average daily trading volume, of 113,600 shares, the short-interest ratio is presently 0.1 days. Currently, 0.4% of the company's stock are sold short.
View Benitec Biopharma's Short Interest

Who are some of Benitec Biopharma's key competitors?

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).

Who are Benitec Biopharma's key executives?

Benitec Biopharma's management team includes the following people:
  • Dr. Jerel A. Banks Ph.D., M.D., CEO & Exec. Chairman (Age 45, Pay $631.7k)
  • Ms. Megan Joan Boston, Exec. Director (Age 48, Pay $348.92k)
  • Mr. Bryan Dulhunty, Chief Financial Officer
  • Dr. Michael Graham, Head of Discovery & Founding Scientist
  • Dr. Craig Lewis, Chief Medical Adviser
  • Dr. Claudia Kloth, Sr. VP of Manufacturing

When did Benitec Biopharma IPO?

(BNTC) raised $0 in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Benitec Biopharma's stock symbol?

Benitec Biopharma trades on the NASDAQ under the ticker symbol "BNTC."

Who are Benitec Biopharma's major shareholders?

Benitec Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (3.14%).

Which institutional investors are buying Benitec Biopharma stock?

BNTC stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley.

How do I buy shares of Benitec Biopharma?

Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Benitec Biopharma's stock price today?

One share of BNTC stock can currently be purchased for approximately $2.94.

How big of a company is Benitec Biopharma?

Benitec Biopharma has a market capitalization of $3.26 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-8,270,000.00 in net income (profit) each year or ($8.10) on an earnings per share basis. Benitec Biopharma employs 14 workers across the globe.

What is Benitec Biopharma's official website?

The official website for Benitec Biopharma is www.benitec.com.

How can I contact Benitec Biopharma?

Benitec Biopharma's mailing address is Level 14 114 William St, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-8692-7222 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.